Table 4.
Attribute: Level | β-coeff | SE | 95% CI | P | ||
---|---|---|---|---|---|---|
Lower | Upper | |||||
Contribution to Resistance: Low | (ref) | |||||
Contribution to Resistance: Med | Mean | −0.9805 | 0.0526 | −1.0837 | −0.8774 | <0.001 |
SD | 0.9669 | 0.0612 | 0.8471 | 1.0868 | <0.001 | |
Contribution to Resistance: High | Mean | −2.5970 | 0.1112 | −2.8151 | −2.3790 | <0.001 |
SD | 2.5959 | 0.1059 | 2.3884 | 2.8034 | <0.001 | |
TX Duration: 3 days* | (ref) | |||||
TX Duration: 7 days* | Mean | 0.1623 | 0.0649 | 0.0352 | 0.2894 | 0.012 |
SD | −0.0424 | 0.1590 | −0.3541 | 0.2693 | 0.790 | |
TX Duration: 14 days* | Mean | −0.3765 | 0.0691 | −0.5119 | −0.2411 | <0.001 |
SD | −0.5161 | 0.0585 | −0.6309 | −0.4014 | <0.001 | |
Likelihood of Side-Effects: 1%* | (ref) | |||||
Likelihood of Side-Effects: 5%* | Mean | −0.3455 | 0.0843 | −0.5106 | −0.1803 | <0.001 |
SD | −0.1442 | 0.1605 | −0.4588 | 0.1704 | 0.369 | |
Likelihood of Side-Effects: 10%* | Mean | −0.4081 | 0.0773 | −0.5596 | −0.2566 | <0.001 |
SD | −0.1898 | 0.1652 | −0.5135 | 0.1339 | 0.251 | |
Likelihood of Side-Effects: 20%* | Mean | −1.0219 | 0.1064 | −1.2305 | −0.8132 | <0.001 |
SD | 1.1816 | 0.0699 | 1.0446 | 1.3186 | <0.001 | |
TX Effectiveness/Failure: 95%/5% | (ref) | |||||
TX Effectiveness/Failure: 90%/10% | Mean | −0.1770 | 0.0879 | −0.3492 | −0.0048 | 0.044 |
SD | 0.5362 | 0.1732 | 0.1967 | 0.8756 | 0.002 | |
TX Effectiveness/Failure: 85%/15% | Mean | −0.6337 | 0.0935 | −0.8169 | −0.4506 | <0.001 |
SD | 0.2842 | 0.3465 | −0.3950 | 0.9635 | 0.412 | |
TX Effectiveness/Failure: 80%/20% | Mean | −0.8753 | 0.0706 | −1.0136 | −0.7370 | <0.001 |
SD | 0.9317 | 0.0813 | 0.7724 | 1.0911 | <0.001 | |
Cost: €10 | (ref) | |||||
Cost: €25 | Mean | −0.2265 | 0.0455 | −0.3157 | −0.1374 | <0.001 |
SD | −0.0354 | 0.1158 | −0.2624 | 0.1916 | 0.760 | |
Cost: €40 | Mean | −0.8017 | 0.0532 | −0.9059 | −0.6975 | <0.001 |
SD | −0.6719 | 0.0700 | −0.8092 | −0.5347 | <0.001 | |
Cost: €100 | Mean | −2.6369 | 0.1189 | −2.8700 | −2.4039 | <0.001 |
SD | 2.7628 | 0.1153 | 2.5368 | 2.9887 | <0.001 | |
Interaction effects (Frame*Parameter)ᵜ | ||||||
Effectiveness*Duration: 7 days | Mean | −0.1595 | 0.0932 | −0.3421 | 0.0232 | 0.087 |
Combination*Duration: 7 days | Mean | −0.2188 | 0.0925 | −0.4001 | −0.0375 | 0.018 |
Effectiveness*Duration: 14 days | Mean | 0.0266 | 0.0996 | −0.1687 | 0.2219 | 0.789 |
Combination*Duration: 14 days | Mean | −0.0783 | 0.0982 | −0.2707 | 0.1141 | 0.425 |
Effectiveness*Side-Effects: 5% | Mean | −0.2160 | 0.1160 | −0.4434 | 0.0113 | 0.063 |
Combination*Side-Effects: 5% | Mean | 0.0361 | 0.1216 | −0.2023 | 0.2746 | 0.766 |
Effectiveness*Side-Effects: 10% | Mean | −0.6317 | 0.1144 | −0.8559 | −0.4074 | <0.001 |
Combination*Side-Effects: 10% | Mean | −0.3367 | 0.1145 | −0.5611 | −0.1123 | 0.003 |
Effectiveness*Side-Effects: 20% | Mean | −0.6517 | 0.1518 | −0.9493 | −0.3541 | <0.001 |
Combination*Side-Effects: 20% | Mean | −0.3578 | 0.1511 | −0.6539 | −0.0616 | 0.018 |
Log-likelihood | −8967.0286 |
Notes: Parameters with significant random effects are shown with SD; *β Coefficients are for the reference Arm 1 (Failure); TX: Treatment, ᵜAll interaction effects were included in the final MIXL model as fixed effects, so no SDs are shown.